Imunon Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
IMNN$0.88+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $5,872,767 | $5,838,566 |
| Investment in debt securities - available for sale, at fair value | - | 9,857,087 |
| Advances and deposits on clinical programs and other current assets | 2,136,192 | 2,545,051 |
| Total current assets | 8,008,959 | 18,240,704 |
| Property and equipment (at cost, less accumulated depreciation and amortization) | 541,272 | 751,906 |
| Other assets: | ||
| Deferred income tax asset | - | 1,280,385 |
| Operating lease right-of-use assets, net | 1,117,133 | 1,595,074 |
| Deposits and other assets | 50,000 | 50,000 |
| Total other assets | 1,167,133 | 2,925,459 |
| Total assets | $9,717,364 | $21,918,069 |
CONSOLIDATED BALANCE SHEETS
(Continued)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable – trade | $1,300,026 | $3,515,192 |
| Other accrued liabilities | 3,033,747 | 3,390,521 |
| Operating lease liabilities - current portion | 452,358 | 485,421 |
| Total current liabilities | 4,786,131 | 7,391,134 |
| Operating lease liabilities - non-current portion | 686,935 | 1,139,293 |
| Total liabilities | 5,473,066 | 8,530,427 |
| Commitments and contingencies | – | – |
| Stockholders’ equity: | ||
| Preferred Stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at December 31, 2024 and 2023) | – | – |
| Common stock - $0.01 par value (112,500,000 shares authorized; 14,500,707 and 9,399,811 shares issued at December 31, 2024 and 2023, respectively, and 14,500,685 and 9,399,789 shares outstanding at December 31, 2024 and 2023, respectively) | 145,007 | 93,998 |
| Additional paid-in capital | 410,987,523 | 401,500,838 |
| Accumulated other comprehensive income | - | 60,796 |
| Accumulated deficit | (406,803,044) | (388,182,802) |
| Total stockholders’ equity before treasury stock | 4,329,486 | 13,472,830 |
| Treasury stock, at cost (22 shares at December 31, 2024 and 2023) | (85,188) | (85,188) |
| Total stockholders’ equity | 4,244,298 | 13,387,642 |
| Total liabilities and stockholders’ equity | $9,717,364 | $21,918,069 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.